Gemtesa and Injection site pain - a phase IV clinical study of FDA data

Summary:

Injection site pain is reported as a side effect among people who take Gemtesa (vibegron), especially for people who are male, 60+ old, also take Vitamin D3, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Injection site pain when taking Gemtesa. It is created by eHealthMe based on reports of 2,622 people who have side effects when taking Gemtesa from the FDA, and is updated regularly.

What is Gemtesa?

Gemtesa has active ingredients of vibegron. eHealthMe is studying from 2,648 Gemtesa users. Check the latest studies of Gemtesa.

What is Injection site pain?

Injection site pain is found to be associated with 1,874 drugs and 1,942 conditions by eHealthMe. Check the latest studies of Injection site pain.

On Jul, 06, 2026

2,622 people reported to have side effects when taking Gemtesa.
Among them, 11 people (0.42%) have Injection site pain.

Could Gemtesa cause Injection site pain?

Among these 11 people:

What is the gender of people who have Injection site pain when taking Gemtesa? *

female: 45.45 %
male: 54.55 %

What is the age of people who have Injection site pain when taking Gemtesa? *

What are other drugs people take besides Gemtesa? *

Vitamin D3: 9 people, 81.82%
Aspirin: 7 people, 63.64%
Gabapentin: 7 people, 63.64%
Zyrtec: 6 people, 54.55%
Albuterol Sulfate: 6 people, 54.55%
Dupixent: 6 people, 54.55%
Sodium Chloride: 5 people, 45.45%
Atorvastatin Calcium: 5 people, 45.45%
Bupropion Hydrochloride: 5 people, 45.45%
Cozaar: 5 people, 45.45%

What are other side effects people have besides Injection site pain? *

Fall: 5 people, 45.45%
Injection Site Discharge: 5 people, 45.45%
Urticaria (rash of round, red welts on the skin that itch intensely): 4 people, 36.36%
Memory Loss: 4 people, 36.36%
Dizziness: 4 people, 36.36%
Dyspnea (difficult or laboured breathing): 4 people, 36.36%
Heart Rate Decreased: 4 people, 36.36%
Heart Rate Irregular: 4 people, 36.36%
Hernia (hernia happens when part of an internal organ or tissue bulges through a weak area of muscle): 4 people, 36.36%
High Blood Pressure: 4 people, 36.36%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 4 people, 36.36%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 3 people, 27.27%
Urticaria (rash of round, red welts on the skin that itch intensely): 2 people, 18.18%
Neurodermatitis (a skin disorder characterized by long lasting itching and scratching): 2 people, 18.18%
Indigestion: 1 person, 9.09%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 1 person, 9.09%
Cough: 1 person, 9.09%
Asthma: 1 person, 9.09%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 9.09%
Ankylosing Spondylitis (type of arthritis affecting the spine): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Gemtesa and have Injection site pain?

- Check whether Injection site pain is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gemtesa:

Gemtesa (2,648 reports)

Browse all side effects of Gemtesa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site pain:

Injection site pain (1,874 drugs)

Browse all the conditions that are associated with Injection site pain:

Injection site pain (1,942 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vibegron (the active ingredients of Gemtesa) and Gemtesa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.